RT Journal Article
T1 Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies
A1 Albiñana, Virginia
A1 Gallardo-Vara, Eunate
A1 Casado-Vela, Juan
A1 Recio-Poveda, Lucía
A1 Botella, Luisa María
A1 Cuesta Martínez, Ángel
AB Research on cancer therapies focuses on processes such as angiogenesis, cell signaling, stemness, metastasis, and drug resistance and inflammation, all of which are influenced by the cellular and molecular microenvironment of the tumor. Different strategies, such as antibodies, small chemicals, hormones, cytokines, and, recently, gene editing techniques, have been tested to reduce the malignancy and generate a harmful microenvironment for the tumor. Few therapeutic agents have shown benefits when administered alone, but a few more have demonstrated clear improvement when administered in combination with other therapeutic molecules. In 2008 (and for the first time in the clinic), the therapeutic benefits of the β-adrenergic receptor antagonist, propranolol, were described in benign tumors, such as infantile hemangioma. Propranolol, initially prescribed for high blood pressure, irregular heart rate, essential tremor, and anxiety, has shown, in the last decade, increasing evidence of its antitumoral properties in more than a dozen different types of cancer. Moreover, the use of propranolol in combination therapies with other drugs has shown synergistic antitumor effects. This review highlights the clinical trials in which propranolol is taking part as adjuvant therapy at single administration or in combinatorial human trials, arising as a good pick and roll partner in anticancer strategies.
PB MDPI
SN 2077-0383
YR 2022
FD 2022-08-04
LK https://hdl.handle.net/20.500.14352/116322
UL https://hdl.handle.net/20.500.14352/116322
LA eng
NO Albiñana V, Gallardo-Vara E, Casado-Vela J, Recio-Poveda L, Botella LM, Cuesta AM. Propranolol: a “pick and roll” team player in benign tumors and cancer therapies. JCM [Internet]. 4 de agosto de 2022 [citado 27 de enero de 2025];11(15):4539. Disponible en: https://www.mdpi.com/2077-0383/11/15/4539
NO Consejo Superior de Investigaciones Científicas (España)
NO Ministerio de Economía y Competitividad (España)
DS Docta Complutense
RD 5 abr 2025